Medtronic (MDT) reported fiscal 2026 fourth‑quarter earnings on June 3, surpassing Wall Street forecasts, and investors responded by scrutinizing the device maker’s market performance.
Revenue Growth
The company posted a 9.9% year‑over‑year increase in revenue, reaching $9.7 billion for the quarter, while full‑year sales grew 8.4%, the strongest expansion in a decade. This top‑line momentum bolsters Medtronic’s standing among healthcare rivals and keeps the stock in focus for investors tracking both traditional markets and emerging blockchain‑related assets.
Valuation and Analyst Outlook
Medtronic shares trade around $78, a notable drop from the 52‑week high of $106.33, yet the forward earnings multiple of 13.5 and a 3.7% dividend yield suggest an appealing price for the market. Analysts at RBC Capital Markets and TD Cowen maintain Buy ratings, projecting price targets of $118 and $119 respectively, while noting that the firm’s price‑to‑sales ratio of 2.8 remains below the roughly 4.0 level of peers such as Abbott and Johnson & Johnson, a factor that may attract investors also interested in crypto‑driven growth sectors.